Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal
M Dediu, C Zielinski, V Preoteasa, A Bulzan · 2026
Read Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal by M Dediu, C Zielinski, V Preoteasa, A Bulzan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13597279.txt.
Description
Dediu, Zielinski, Preoteasa, and Bulzan reappraised treatment order for early triple-negative breast cancer in twenty twenty-six. For stage I tumors of this aggressive subtype, guidelines favor chemotherapy before surgery, a plan borrowed from trials in larger tumors.
The authors reviewed registry studies and meta-analyses comparing chemo-first with surgery-first care in stage I disease. The retrospective data linked surgery first, then chemotherapy, to better survival. Adding platinum drugs before surgery raised tumor disappearance rates but gave inconsistent survival gains. Capecitabine given after surgery, by contrast, showed a robust long-term benefit. The authors propose a stage-specific plan: operate first, then give chemotherapy built on standard drug families plus capecitabine, avoiding possible undertreatment from the chemo-first route in small tumors.
Catalog record
| CREATOR | M Dediu, C Zielinski, V Preoteasa, A Bulzan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |